Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

随着2024年这些突破性临床试验的相继发表，GLP-1类药物展现出远超预期的治疗潜力。从最初的糖尿病治疗，到减重管理，再到阿尔茨海默病、心血管疾病、慢性肾病、骨关节炎、多囊卵巢综合征等多个重大疾病领域，这类药物正在重新定义现代医学的治疗范式。特别值得 ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...

The most negatively impacted sectors are frozen, refrigerated, general food and beverages. Circana found GLP-1 users’ monthly ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

A top NYC weight-loss doctor shared the surprising skin complication that he’s encountered in patients using GLP-1 drugs like ...

Hello, Health Rounds Readers! Today we feature a study that found yet another potential health benefit of GLP-1 drugs, this ...